前列腺素E1治疗肝硬化的临床疗效及安全性评价

Clinical efficacy and security evaluation of prostaglandin E1 on liver cirrhosis

目的观察前列腺素E1治疗肝硬化的临床疗效,并对其安全性进行评估。方法选取2011年7月~2012年7月台州医院收治的肝硬化患者68例,随机均分为治疗组(n=34)和对照组(n=34)。对照组接受常规药物治疗,治疗组在对照组基础上接受前列腺素E1治疗,对比分析2组疗效及不良反应。结果与治疗前相比,治疗后2组患者白蛋白数量均明显增加,治疗组由(27.9±4.1)g/L增加到(36.5±4.3)g/L,对照组由(27.8±4.0)g/L增加到(31.7±4.2)g/L,差异均有统计学意义(P<0.05);2组间比较,差异也有统计学意义(P<0.05)。治疗后,2组患者丙氨酸氨基转移酶和门冬氨酸氨基转移酶含量均明显下降(P<0.05),与对照组相比,治疗组减少更明显(P<0.05)。治疗组总有效者28例,约占82.35%,对照组仅有11例,约占32.35%,2组比较差异有统计学意义(P<0.05)。结论前列腺素E1治疗肝硬化能有效改善患者肝功能指标,临床效果好、安全性高。

Objective To observe the clinical effects of prostaglandin E1 on liver cirrhosis patients and evaluate its security. Methods 68 cases with liver cirrhosis admitted in Luqiao hospital were randomly divided into experimental group(34 cases)and control group(34 cases)equally. Patients in control group were received normal therapy,while in experimental group were added prostaglandin E1 on basis of normal therapy. The efficacy and adverse reactions were observed and compared. Results Compared with before treatment,the average value of albumin in two groups were increased obviously,which in experimental group from (27.9 ±4.1)g/L to (36.5 ±4.3)g/L,control group from (27.8 ±4.0)g/L to (31.7 ±4.2)g/L,the differences were significant(P<0.05 ),and the difference between two groups was significant(P<0.05 ),too. The content of alanine aminotransferase and aspartase aminotransferase in two groups were decreased significantly(P<0.05 ),and experimental group was more lower than control group(P<0.05 ). The number of effcacy in experimental group was 28 and account for 82.35%,while in control group was 1 1 and account for 32.35%,the difference was significant(P<0.05). Conclusion Prostaglandin E1 can improve liver function,and has good clinical effects and high security in treatment with liver cirrhosis patients.